Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease.
Introduction: Levodopa is the most efficacious and best-tolerated drug for treating Parkinson's disease (PD). To improve the treatment of PD, recent research initiatives have aimed to optimize the pharmacokinetic plasma behavior of L-dopa. Areas covered: This non-systematic, narrative drug evaluation brings the therapeutic value of IPX066 up for discussion. IPX066 is an orally applied levodopa/carbidopa containing formulation with modified drug release. It is rapidly absorbed, similar to conventional immediate-release levodopa preparations. The IPX066 capsule continuously releases levodopa during its passage through the gastrointestinal tract. Expert opinion: IPX066 provides more constant therapeutic levodopa plasma concentrations over longer periods. Furthermore, the IPX066 study program showed superior efficacy of IPX066 than conventional oral levodopa/carbidopa preparations for the treatment of motor complications, particularly with OFF intervals. IPX066 also reduced the frequency of oral levodopa intake. IPX066 may also improve the patient´s compliance due to its simplified drug regimen. The marketing of IPX066 outside the US is complex since in countries like Germany, health-care payers only consider innovation in terms of mode of action whereas innovation of pharmacokinetic and pharmacodynamic properties is disregarded.